SamanthaMalloryMD

Pediatric Hematology & Oncology • Des Moines, IA

Physician

Join to view full profile

Dr. Mallory is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mallory's full profile

Already have an account?

Office
1215 Pleasant St Ste 514

Des Moines, IA 50309
Phone+1 515-241-8912

Fax+1 515-241-8988

Education & Training

University of Oklahoma College of MedicineFellowship, Pediatric Hematology/Oncology, 2013 - 2016
University of Oklahoma Health Sciences CenterResidency, Pediatrics, 2009 - 2012
University of Oklahoma College of MedicineClass of 2009

Certifications & Licensure

IA State Medical License 2016 - 2027
OK State Medical License 2011 - 2023
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2014-2017

Clinical Trials

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
RECRUITING
Roles: Principal Investigator
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2020 Oct 13
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
ACTIVE_NOT_RECRUITING
Roles: Principal Investigator
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2018 May 14
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy Start of enrollment: 2014 Jul 30
ACTIVE_NOT_RECRUITING
NA
Roles: Principal Investigator
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Start of enrollment: 2020 Oct 19
RECRUITING
PHASE2
Roles: Principal Investigator
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2020 Jul 20
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Start of enrollment: 2018 May 24
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Apr 17
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2020 Dec 17
SUSPENDED
PHASE2
Roles: Principal Investigator
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Start of enrollment: 2020 Jan 15
RECRUITING
PHASE3
Roles: Principal Investigator
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Aug 23
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Start of enrollment: 2014 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Start of enrollment: 2020 Jan 31
RECRUITING
PHASE3
Roles: Principal Investigator
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2021 May 03
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Start of enrollment: 2017 Jul 31
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Start of enrollment: 2017 Nov 17
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Project: Every Child for Younger Patients With Cancer Start of enrollment: 2015 Nov 03
RECRUITING
Roles: Principal Investigator
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 28
COMPLETED
PHASE2
Roles: Principal Investigator
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25
RECRUITING
PHASE3
Roles: Principal Investigator
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Start of enrollment: 2020 Jul 21
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors Start of enrollment: 2017 Dec 06
COMPLETED
Roles: Principal Investigator
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Start of enrollment: 2019 Jul 03
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Start of enrollment: 2020 Dec 07
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Start of enrollment: 2019 Oct 31
RECRUITING
PHASE3
Roles: Principal Investigator
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2019 Nov 08
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Start of enrollment: 2021 Sep 14
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States Start of enrollment: 2022 Mar 14
ACTIVE_NOT_RECRUITING
Roles: Principal Investigator
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Start of enrollment: 2021 Jul 13
RECRUITING
PHASE2
Roles: Principal Investigator
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Start of enrollment: 2017 Jun 19
RECRUITING
PHASE2
Roles: Principal Investigator
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Start of enrollment: 2022 Apr 01
RECRUITING
PHASE3
Roles: Principal Investigator
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Start of enrollment: 2021 Oct 05
RECRUITING
PHASE3
Roles: Principal Investigator
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors Start of enrollment: 2022 May 10
RECRUITING
PHASE3
Roles: Principal Investigator
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma Start of enrollment: 2022 Aug 04
RECRUITING
PHASE3
Roles: Principal Investigator
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Start of enrollment: 2023 May 11
RECRUITING
PHASE3
Roles: Principal Investigator
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Start of enrollment: 2022 Apr 18
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Start of enrollment: 2023 Aug 24
RECRUITING
PHASE3
Roles: Principal Investigator
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) Start of enrollment: 2022 May 31
SUSPENDED
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

34 citations
OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.
Rheal A. Towner, Nataliya Smith, Debra Saunders, Chase A. Brown, Xue Cai
Translational Oncology. 2019-02-01
30 citations
ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models
Jadith Ziegler, Richard Pody, Patricia Coutinho de Souza, Blake Evans, Debra Saunders
Neuro-Oncology. 2016-07-14
15 citations
Inhibition of pediatric glioblastoma tumor growth by the anti-cancer agent OKN-007 in orthotopic mouse xenografts
Patricia Coutinho de Souza, Samantha Mallory, Nataliya Smith, Debra Saunders, Xiao-Nan Li
Plos One. 2015-08-06